Royalty Pharma (RPRX) Enterprise Value (2019 - 2026)

Royalty Pharma has disclosed Enterprise Value across 8 years of filings, most recently posting $2.4 billion for Q1 2026.

• Enterprise Value for Q1 2026 came in at $2.4 billion, up 21.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 21.99% YoY), and the FY2025 annual result was $2.6 billion, up 7.97% from the prior year.
• Enterprise Value came in at $2.4 billion for Q1 2026 at Royalty Pharma, down from $2.6 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $3.1 billion in Q4 2023 to a low of $1.4 billion in Q2 2023.
• The 5-year median for Enterprise Value is $2.4 billion (2024), against an average of $2.3 billion.
• Across the five-year window, Enterprise Value sank 44.83% in 2022 and soared 70.46% in 2025, its largest moves.
• Royalty Pharma's Enterprise Value stood at $2.2 billion in 2022, then surged by 40.15% to $3.1 billion in 2023, then declined by 21.35% to $2.4 billion in 2024, then advanced by 7.97% to $2.6 billion in 2025, then decreased by 6.17% to $2.4 billion in 2026.
• The last three Enterprise Value figures came in at $2.4 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.